Drug Profile

RABI 767

Alternative Names: RABI-767

Latest Information Update: 18 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Mayo Clinic
Developer Arrivo BioVentures; Lamassu Pharma
Class Anti-inflammatories; Small molecules
Mechanism of Action Lipase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase II Pancreatitis

Most Recent Events

15 Jul 2024 RABI 767 receives Fast Track designation for Pancreatitis [Intraperitoneal, Injection] in USA
26 Feb 2024 Phase-II clinical trials in Pancreatitis in USA (Intraperitoneal) (NCT06080789)
29 Nov 2023 Phase-I clinical trials in Pancreatitis (In volunteers) (Intraperitoneal before November 2023 (9405148)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com